Table 5.
Risk Factors Associated with Poor Outcomes* after TNF-α Inhibitor Treatment in Patients with Ulcerative Colitis (n=113)
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| p-value | p-value | Adjusted HR†
(95% CI) |
||
| Age (>40/≤40 yr) | 0.639 | |||
| Sex (male/female) | 0.401 | |||
| CRP (>5/≤5 mg/L) | 0.001 | 0.001 | 2.25 (1.37–3.70) | |
| Disease extent (extensive/left-sided) | 0.850 | |||
| TNF-α inhibitor (infliximab/adalimumab) | 0.229 | 0.208 | 1.45 (0.81–2.56) | |
TNF, tumor necrosis factor; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein.
*Poor outcomes are defined as the sum of the following events: all-cause hospitalization, ulcerative colitis-related hospitalization, corticosteroid prescription, discontinuation of TNF-α inhibitors, and switching to a secondary TNF-α inhibitor; †A HR of >1 indicates a benefit of infliximab compared with adalimumab.